Strategic Investment Novo Holdings invested in HST Pathways in June 2026, signaling strong growth potential and expanded funding ability to scale sales, expand product reach, and pursue larger ASC wins.

Product Momentum Recent enhancements to the HST platform and recognition as ASC software of the year indicate a continuously improving product, creating upsell opportunities for existing clients and attracting new ASCs seeking best-in-class features.

Expansion Partnerships New partnership with J.L. Morgan & Associates enhances patient experience and quality measurement capabilities, presenting cross-sell opportunities to ASCs and hospitals needing CAHPS and outcomes integrations.

Market Leadership As a category leader with a growing client base (over 2,000 clients) and consistent industry recognition, there is a strong case to target mid-market and enterprise ASCs seeking scalable, integrated software across the patient journey.

Financial Scale Revenue in the mid to high hundreds of millions positions HST Pathways for larger contract values and multi-site deployments, suggesting opportunity for multi-location growth deals, renewals, and premium support partnerships.